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ABSTRACT. Objective. To summarize the work performed by the Outcome Measures in Rheumatology
(OMERACT) Ultrasound (US) Task Force on the validity of different US measures in rheumatoid
arthritis (RA) and juvenile idiopathic arthritis (JIA) presented during the OMERACT 11 Workshop.
Methods. The Task Force is an international group aiming to iteratively improve the role of US in
arthritis clinical trials. Recently a major focus of the group has been the assessment of respon-
siveness of a person-level US synovitis score in RA: the US Global Synovitis Score (US-GLOSS)
combines synovial hypertrophy and power Doppler signal in a composite score detected at joint
level. Work has also commenced examining assessment of tenosynovitis in RA and the role of US
in JIA. 
Results. The US-GLOSS was tested in a large RA cohort treated with biologic therapy. It showed
early signs of improvement in synovitis starting at Day 7 and increasing to Month 6, and demon-
strated sensitivity to change of the proposed grading. Subsequent voting questions concerning the
application of the US-GLOSS were endorsed by > 80% of OMERACT delegates. A standardized
US scoring system for detecting and grading severity of RA tenosynovitis and tendon damage has
been developed, and acceptable reliability data were presented from a series of exercises. A prelim-
inary consensus definition of US synovitis in pediatric arthritis has been developed and requires
further testing. 
Conclusion. At OMERACT 11, consensus was achieved on the application of the US-GLOSS for
evaluating synovitis in RA; and work continues on development of RA tenosynovitis scales as well
as in JIA synovitis. (First Release Nov 15 2013; J Rheumatol 2014;41:379–82; doi:10.3899/
jrheum.131084)
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The OMERACT Ultrasound Task Force met for the first
time at OMERACT 7 in 2004 with the aim of investigating
the role of ultrasound (US) in rheumatology, and developing
its metric properties, particularly in the field of inflam-
matory arthritis. The first step was to develop and publish
standardized definitions of US pathologies1. The group then
performed a systematic review of the metric properties of
US for the detection of synovitis at the individual joint level
(for multiple peripheral joints) that highlighted gaps in the
literature, including a lack of reliability data with respect to
intraoccasion, intrareader, and interreader reliability2.
Following this work, through a series of iterative intra-
observer and interobserver reliability exercises, the group
developed and tested definitions and scoring of joint
pathologies related either to inflammation or to structural
damage in rheumatoid arthritis (RA). This subsequently
resulted in the ongoing development of a US GLObal
Synovitis Score (US-GLOSS), at the whole patient level,
that would be proposed for application in multicenter thera-
peutic trials, providing a responsive US scoring system in
patients with RA3. 
Following the decision taken during the OMERACT 10
meeting, the group expanded the validation of US in RA by
working on tenosynovitis. Thus, starting from a systematic
literature review of US definitions, scoring systems, and
validity for tendon involvement in RA, a series of reliability
exercises was performed that focused on the detection and
scoring of tenosynovitis and tendon damage in patients with
RA4,5,6. It was also agreed at OMERACT 10 to work on US
as an outcome measure in pediatric arthritis. Based on a
systematic literature review, the group started work on the
definition of a normal joint that will lead to definitions of
pediatric joint synovitis. At the same time future areas of
standardization were agreed on7. 
The aim of the present article is to summarize the recent
work performed by the OMERACT US Group in the
assessment of responsiveness for a number of measures in
RA, as presented during the OMERACT 11 Workshop.
US-GLOSS
The concept of developing a US-based scoring system for
synovitis in RA at the patient level was agreed on through
group discussions and feedback sessions at OMERACT 10
in 20108. This decision was based on the need for
integrating the components of synovitis (i.e., hypoechoic
synovial hypertrophy and synovial Doppler signal) in a
unique global score of joint inflammatory activity in RA.
This scoring system, applied at the patient level by means of
a multijoint US assessment, should allow an objective
followup of patients under treatment and should provide a
feasible and objective instrument for evaluating disease
activity in patients with RA8. The work developed by the
group in the assessment of reliability in the detection and
scoring of RA synovitis demonstrated positive results at the
joint level8,9,10,11,12,13. In addition, recent longitudinal
studies applying either extensive or reduced US joint counts
have shown the feasibility of US for following patients
under treatment. However, many differences have been
reported in the scoring system used (i.e., greyscale
synovitis, Doppler, both modalities) as well as in the number
of joints assessed and in the correlations (construct validity)
between US scores and clinical and laboratory find-
ings8,14,15,16,17,18,19. Thus, development of a US-GLOSS
required testing of sensitivity to change of the OMERACT
synovitis scoring system in a multicenter study. 
During the OMERACT 11 Workshop, results were
presented of the application of the US-GLOSS in patients
with RA. The study represented the first international,
multicenter, prospective, open-label therapeutic trial that
used the OMERACT US-GLOSS and tested the response to
treatment with abatacept and methotrexate (MTX) in
patients with RA and inadequate response to MTX (manu-
script in preparation). In this study, US responsiveness was
used as the primary objective. US-GLOSS, by combining
synovial hypertrophy and power Doppler (PD) signal in a
composite score applied at joint level, was able to demon-
strate, at patient level, early signs of improvement in
synovitis from days 7, 15, and 29, increasing up to Month
63. A reduced subset of joints (GLOSS) that best represented
the global PDUS score for paired 22 joints of all patients
over 3 timepoints was identified at baseline (BL) and days
85 and 169, based on principal component analysis. The
sensitivity to change was assessed for GLOSS and the
existing 12-joint and 7-joint sets using standardized
response mean (SRM). When the GLOSS was compared
with the 2 previously published reduced joint sets (assessed
bilaterally), the mean change from BL improved up to Day
169 for all 3 measures, with similar SRM. 
Based on these results, at the plenary session 4 voting
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questions for US synovitis were presented to participants for
potential endorsement. The first voting question: “Do you
support continuing to evaluate US in assessing synovitis by
using greyscale and Doppler modalities separately?” was
endorsed by > 80% of the OMERACT delegates to have
appropriate validation data. The second question: “In
addition, do you support to continue development and
subsequent validation of a combined score?” received 70%
of the vote. The third question: “Do you support the idea to
improve the feasibility of US assessment by developing and
validating a reduced joint count?” was endorsed by > 80%
of delegates. Finally, the fourth question: “Do you support
implementation of US as a secondary/exploratory outcome
in therapeutic clinical trials?” received 80% of the vote. 
Tenosynovitis
The work on tenosynovitis was essentially focused on the
assessment of discrimination of US for detecting and
scoring tendon involvement in RA. The starting point was a
systematic literature review of US definitions, scoring
systems, and metric properties for tenosynovitis and tendon
damage in RA4. Then, based on the limited available data on
reliability, the group started a series of exercises focused
initially on testing the reliability of US in detecting lesions,
and subsequently aimed at assessing the reliability of US in
scoring tenosynovitis and tendon damage5,6. A Delphi
process was previously performed on defining the scoring
systems for tenosynovitis6. During the US Workshop at
OMERACT 11, results of the literature review were
presented with focus on the different aspects of validity4.
The results of the intraobserver and interobserver reliability
exercises were also reported: moderate-to-good intra-
observer and interobserver reliability for tenosynovitis and
tendon damage were demonstrated for both greyscale and
PD. Then, following the above Delphi consensus process
(which examined agreement of a group of experts on
US-defined tenosynovitis and US scoring systems of
tenosynovitis in RA), a second patient-based reliability
exercise was performed. The results showed good intra-
observer reliability and moderate to good interobserver
reliability for B-mode and PD modalities6. A formal
research agenda was also developed including a third
patient-based reliability exercise on tendon damage in RA,
performed in June 2012 in Amsterdam, with the aim of
developing an OMERACT atlas on scoring tenosynovitis
and tendon damage in RA.
Pediatric Arthritis
Several publications have highlighted the capability of US
to detect joint involvement in pediatric arthritis revealing
the high frequency of asymptomatic findings. At
OMERACT 11 the group reported results of a systematic
literature review demonstrating that validity of US in
pediatric arthritis had not yet been established and
standardized7. Using results of an international survey on
the use of US in pediatric rheumatology as the basis for
future work, the first identified area for standardization was
the definition and detection of US synovitis in juvenile
idiopathic arthritis. Such pathology does not differ from that
observed in adults; however, the appearance of the joint can
vary according to the age and maturation of the child, with
the presence of variable amounts of vascularized epiphyseal
cartilage. This makes the distinction of normal findings
from synovitis more challenging. The work of the group has
also been focused on developing definitions of normal joint
components for different age groups through a Delphi
consensus process and by testing them in a reliability
exercise involving healthy children, performed in Madrid in
March, 2012. The preliminary results were presented during
the session. The group is now developing preliminary
definitions for common US-detected pathologies in
pediatric rheumatology diseases. 
At OMERACT 11 all aspects presented on synovitis
were strongly endorsed by OMERACT delegates, further
supporting US as a good outcome measure for evaluating
activity and responsiveness in RA. Consensus was achieved
on the application of a US-GLOSS scoring system for
synovitis in RA and its use in therapeutic clinical trials.
Further randomized controlled studies are needed to confirm
these results and explore predictive validity in terms of
structural damage and stratification of “patients at risk” for
severe disease. 
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